Connor, Clark & Lunn Investment Management (CC&L)’s Amylyx Pharmaceuticals AMLX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.4M | Sell |
1,154,485
-45,206
| -4% | -$290K | 0.03% | 476 |
|
|
2025
Q1 | $4.25M | Sell |
1,199,691
-63,662
| -5% | -$225K | 0.02% | 539 |
|
|
2024
Q4 | $4.78M | Buy |
1,263,353
+382,608
| +43% | +$1.45M | 0.02% | 493 |
|
|
2024
Q3 | $2.85M | Buy |
880,745
+258,818
| +42% | +$839K | 0.01% | 590 |
|
|
2024
Q2 | $1.18M | Buy |
621,927
+95,239
| +18% | +$181K | 0.01% | 812 |
|
|
2024
Q1 | $1.5M | Buy |
526,688
+270,082
| +105% | +$767K | 0.01% | 759 |
|
|
2023
Q4 | $3.78M | Buy |
256,606
+132,151
| +106% | +$1.95M | 0.02% | 507 |
|
|
2023
Q3 | $2.28M | Buy |
+124,455
| New | +$2.28M | 0.01% | 582 |
|